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A B S T R A C T
Objectives: Vertebral osteomyelitis (VO) is a compelling clinical entity for clinicians because of its
insidious and indolent course, which makes diagnosis difficult.
Methods: All patients with a suspected diagnosis of VO were analyzed over an 8-year period (January
2009 to January 2017). The UDIPROVE protocol (UDIne PROtocol on VErtebral osteomyelitis) was applied
in all cases. The primary endpoint was the performance of the UDIPROVE protocol to obtain the causal
bacteria of infection.
Results: During the study period, 133 episodes of confirmed VO were observed. The etiology of infection
was obtained in 73.6% of cases: 70.5% were gram-positive, 16.3% were gram-negative, and 13.2% were
mycobacteria. 18F-Fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/
CT) showed that for tubercular VO, the median standard uptake value (SUV) was higher when compared
with VO caused by other bacteria. Clinical cure at the end of therapy was reported in 85.7% of patients.
Previous antimicrobial therapy and a delay of more than 5 days in performing biopsy were associated
with an undiagnosed etiology of VO. Targeted antibacterial therapy and follow-up with FDG-PET/CT were
associated with clinical cure at the end of therapy, while the involvement of more than two vertebrae and
inadequate drainage were associated with failure.
Conclusions: Rigorous application of the UDIPROVE protocol allowed the causative pathogens of VO to be
obtained – at about twice the rate reported in the literature. The use of FDG-PET/CT for the follow-up of
infection was more reliable when compared to magnetic resonance imaging (MRI).
© 2019 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Vertebral osteomyelitis (VO) is a compelling clinical entity for
clinicians because of its insidious and indolent course, which
makes diagnosis difficult. The diagnosis of VO can often be delayed
by several months and the disease may initially be misdiagnosed
and mismanaged as a degenerative process. Consequently, patients
often develop destructive lesions or neurological complications. In
this setting, an elevated C-reactive protein (CRP) level in patients* Corresponding author at: Infectious Diseases Clinic, Department of Health
Sciences, University of Genoa, Genoa and Hospital Policlinico San Martino - IRCCS,
Genoa, Italy.
E-mail address: Matteo.Bassetti@hsanmartino.it (M. Bassetti).
https://doi.org/10.1016/j.ijid.2019.10.010
1201-9712/© 2019 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).with back pain, although not specific, has a sensitivity that can
range from 94% to 100% (Zimmerli, 2010; Gupta et al., 2014).
Overall, the etiology of infection in VO is obtained in less than
40% of cases, making the choice of antimicrobial regimen and
duration of therapy challenging (Chew and Kline, 2001). With the
exception of septic patients and patients with neurological
compromise, empiric antimicrobial therapy should be withheld
whenever possible until a microbiological diagnosis is confirmed.
An image-guided aspiration biopsy is recommended for patients
with suspected VO when a microbiological diagnosis has not been
established by blood cultures (BC) or serological tests; however,
the rate of diagnosis with an image-guided biopsy, as reported in
the literature, is about 30–40% (Berbari et al., 2015).
No indications for follow-up with magnetic resonance imaging
(MRI) in patients with VO who have a favorable clinical andciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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the international guidelines (Berbari et al., 2015), considering the
limits of the method. Thus, the role of positron emission
tomography (PET) has been assessed over recent years, considering
its high sensitivity for detecting osteomyelitis. A negative PET scan
excludes the diagnosis of osteomyelitis, including VO (Ohtori et al.,
2010; Hungenbach et al., 2013).
The aim of this study was to investigate the rigorous application
of the UDIPROVE protocol (UDIne PROtocol on VErtebral osteomy-
elitis) to obtain the causative pathogens of VO with vertebral
biopsy, and the role of 18F-fluorodeoxyglucose PET/computed
tomography (FDG-PET/CT) in the diagnosis and follow-up of
infection and comparison with MRI.
Materials and methods
Study design
This was a prospective observational study conducted in a large
tertiary level hospital in Italy over an 8-year period (January 2009
to January 2017). During the study period, all consecutive adult
patients (age 18 years) with a suspected diagnosis of VO were
analyzed. The UDIPROVE protocol was applied in all cases, as
reported in Figure 1. The study was preapproved by the local ethics
committee and was conducted in accordance with the principles of
the Declaration of Helsinki.
Data collection and definitions
Patient data were collected prospectively from the medical
records, computerized hospital databases, and/or clinical charts
using a standard form. These included demographic characteristics,
clinical and laboratory findings, baseline comorbidities, radiological
findings, relapse of infection, microbiological data, the Charlson
Comorbidity Index, date and type of surgery (if performed), source of
infection, persistent bacteremia, development of septic shock,
duration of hospital stay, duration of definitive antibiotic therapy,
clinical treatment failure, and 30-day mortality.
At the time of diagnosis, the patients underwent MRI and/or
FDG-PET/CT (first visit). All patients who underwent FDG-PET/CT
were on a low carbohydrate–fat allowed diet for 24 h before
the FDG-PET/CT was performed; they fasted for the 6 h prior to
18F-FDG injection, according to the local protocol.Figure 1. The UDIPROVE algorithm.
ID: infectious diseasesThe following definitions were established prior to data
analysis: ‘relapse’ was defined as a new diagnosis of VO caused
by the same organism after clinical and microbiological resolution
of a previously treated episode of VO; ‘time to biopsy’ was defined
as the number of days that elapsed between the diagnosis of VO
and the vertebral biopsy (when performed); ‘persistent infection’
was defined in the case of a patient still being treated for VO at the
3-month follow-up, without resolution of the described symp-
toms; ‘clinical treatment failure’ was defined as a lack of response
to the definitive antimicrobial regimen, as reflected by the
presence of any of the following after 45 days of therapy:
ongoing fever, leukocytosis, or other clinical signs of infection that
could not be attributed to causes other than VO; ‘30-day mortality’
was defined as death from any cause within the 30 days following
the diagnosis of VO.
Synchronous or metastatic foci of infection were identified by
means of clinical and imaging examinations. When present, fluid
collections and abscesses were drained and the fluid cultured.
Coagulase-negative staphylococci (CoNS) and other skin commen-
sals were considered etiologically irrelevant unless they were
isolated from two or more sets of BC and their causative role was
consistent with clinical data. Adequate control of the source of
infection was defined as the removal of any preexisting contami-
nated central venous catheter, as well as the drainage of vertebral
abscesses or other fluid collections, with these being performed
within 24 h after the onset of infection. Patients who were
diagnosed with VO based on at least one imaging study and/or
blood or tissue culture results were treated according to the
Infectious Diseases Society of America (IDSA) guidelines for
vertebral osteomyelitis (Berbari et al., 2015). Three months after
inclusion (second visit), all surviving patients underwent MRI and/
or FDG-PET/CT.
Endpoints and statistical analysis
The primary endpoint was the performance of the UDIPROVE
protocol to obtain the causal bacteria of infection. Secondary
endpoints were the role of FDG-PET/CT in diagnosis and follow-up
and the analysis of clinical cure at the end of therapy.
Between-group differences were assessed with the Chi-square
test or Fisher’s exact test (for categorical variables) and the two-
tailed t-test or Mann–Whitney test (for continuous variables), as
appropriate. Univariate and multivariate analyses were used to; TB: tuberculosis.
Table 1
Etiology of vertebral osteomyelitis.





Streptococcus spp 24 (24.4)
Enterococcus spp 4 (4.1)
Others 4 (4.1)
Gram-negative 16 (16.3)
Escherichia coli 8 (8.1)
Klebsiella pneumoniae 4 (4.1)
Others 4 (4.1)
Mycobacterium tuberculosis 13 (13.3)
MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive
Staphylococcus aureus; CoNS, coagulase-negative staphylococci.
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etiology of VO, clinical treatment failure, and clinical success in the
study population. Possible confounding factors and interactions
were weighted during analyses with a backward stepwise
selection and considering p  0.05 for all variables, to determine
the effects of all anamnestic, clinical, and therapeutic variables on
the outcomes. All reported p-values are two-tailed. Wald confi-
dence intervals (CI) and odd ratios (OR) were computed based on
estimated standard errors. All analyses were done using IBM SPSS
Statistics version 20.0 (IBM Corp., Armonk, NY, USA).
Results
During the study period, 133 episodes of confirmed VO were
observed. As reported in Table 1, the etiology of infection was
obtained in 98 cases (73.6%) (BC + vertebral biopsy/drainage)
according to the UDIPROVE algorithm (Figure 1). The most
frequently isolated bacteria were gram-positive (70.5%), followed
by gram-negative (16.3%) and mycobacteria (13.2%). Among the
gram-positive bacteria, Streptococcus spp accounted for 24.4% of
cases, followed by methicillin-resistant Staphylococcus aureus
(MRSA) (19.4%). Biopsy results with or without antimicrobial
washout are reported in Figure 2.
The mean standard uptake value (SUV), CRP, and white blood
cell count (WBC) values at the time of diagnosis (first visit) and at
follow-up (second visit) are reported in Figure 3. StatisticallyFigure 2. Biopsy results with and wsignificant differences were observed for SUV (p < 0.001) and CRP
(p < 0.001) values.
Finally, the SUV values in subgroups of patients with VO at
follow-up (second visit) are reported in Figure 4: patients with or
without a tubercular etiology, the presence or absence of
endocarditis, Staphylococcus aureus etiology or others, and two
or more than two vertebrae involved in infection. Statistically
significant differences in SUV values were observed for tubercular
etiology or not (p < 0.001) at follow-up.
Table 2 reports the baseline characteristics and outcomes of the
study population along with the univariate analysis of risk factors
for clinical success or failure. Vertebral biopsy/drainage was
performed in 101 patients (75.9%), and 14-day antimicrobial
treatment discontinuation before vertebral biopsy was obtained in
98 patients (73.7%). Concomitant endocarditis was observed in 18
cases (13.5%). The mean SUV value was 7.2  3.3, and diagnosis and
follow-up with FDG-PET/CT was performed in 59 patients (44.3%).
All patients underwent MRI at the time of diagnosis and at follow-
up. Clinical cure at the end of therapy was reported in 114 patients
(85.7%), and 30-day mortality was 10.5%.
Univariate analysis of risk factors for clinical success or failure
showed that the involvement of more than two vertebrae (94.7%
vs. 24.5%, p < 0.001), mean SUV value (7.6  3.8 vs. 7  3.6, p = 0.03),
and inadequate source control of infection (84.2% vs. 7.9%,
p < 0.001) were more frequently observed in patients with failure
of therapy, compared with the clinical cure group. Conversely,
targeted antibacterial therapy (78.9% vs. 42.1%, p < 0.001) and
follow-up with FDG-PET/CT (50% vs. 10.5%, p < 0.001) were more
frequently reported in the clinical cure group. No differences in 30-
day mortality were observed. Follow-up with FDG-PET/CT showed
that a decrease in the SUV of >30% from the baseline value was
associated with clinical cure at the end of therapy. For tubercular
VO, the mean SUV at the time of diagnosis was higher when
compared with those of VO caused by other bacteria (11.4  3.7 vs.
7  2.3, p < 0.001).
Logistic regression analysis showed that previous antimicrobial
therapy and a delay of more than 5 days in performing biopsy were
associated with an undiagnosed etiology of VO, as reported in
Table 3A. Targeted antibacterial therapy and follow-up with FDG-
PET/CT were associated with clinical cure at the end of therapy,
while the involvement of more than two vertebrae and inadequate
drainage of infection were associated with failure of therapy
(Table 3B).ithout antimicrobial washout.
Figure 3. Mean SUV, CRP, and WBC values at the time of diagnosis (first visit) and at follow-up (second visit).
SUV: standard uptake value; CRP: C-reactive protein; WBC: white blood cell count.
Figure 4. SUV values in subgroups of patients with vertebral osteomyelitis at follow-up (second visit).
SUV: standard uptake value; VO: vertebral osteomyelitis; TB: tuberculosis.
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The study data showed that the rigorous application of the
UDIPROVE protocol allowed the causative pathogens of VO to be
obtained in almost 75% of cases, a higher rate when compared with
data reported in the literature (Berbari et al., 2015). Of importance,
the use of FDG-PET/CT was more reliable for the follow-up of
infection when compared to MRI. As a consequence, targeted
antibacterial therapy was independently associated with clinical
cure of VO. Finally, previous antimicrobial therapy and a delay ofmore than 5 days in performing biopsy were associated with an
undiagnosed etiology of VO, while the involvement of more than
two vertebrae and inadequate drainage of infection were
associated with treatment failure.
The UDIPROVE protocol was associated with a high rate of
diagnosis in patients with VO. In the literature, the sensitivity of
image-guided biopsy in evaluated studies is about 40% (Sehn and
Gilula, 2012). Bhavan et al. showed that the yield of causative
pathogens increased with open biopsy (93%) compared with
needle aspiration biopsy (48%) (Bhavan et al., 2010). Of note, VO is
Table 2
Baseline characteristics and outcomes of the study population, and univariate analysis of risk factors for clinical cure or failure of therapy.
Variables Total population Clinical cure Failure of therapy p-Value
N = 133 (%) n = 114 (%) n = 19 (%)
Age (years), mean  SD 65.7  13.9 66.3  14.1 65.6  13.4 0.94
Male sex 68 (51.1) 58 (50.8) 10 (52.6) 1.0
Charlson Comorbidity Index, mean  SD 2.5  1.4 2.4  1.5 2.5  1.6 1.0
Previous spinal surgery 20 (15) 18 (15.7) 2 (10.5) 0.73
Previous antimicrobial therapy (30 days) 112 (84.2) 95 (83.3) 17 (89.4) 0.74
14-day antimicrobial treatment discontinuation before vertebral biopsy 98 (73.7) 85 (74.5) 13 (68.4) 0.58
>2 vertebrae involved 46 (34.5) 28 (24.5) 18 (94.7) <0.001
Endocarditis 18 (13.5) 15 (13.1) 3 (15.7) 0.91
Other localization of infection 41 (30.8) 30 (26.3) 11 (57.8) 0.01
Biopsy/drainage performed 101 (75.9) 88 (77.1) 13 (68.4) 0.34
Blood culture positivity 34 (25.5) 30 (26.3) 4 (21) 0.62
SUV value, mean  SD 7.2  3.3 7  3.6 7.6  3.8 0.03
CRP concentration (mg/l), mean  SD 42.2  32.9 40.2  31.7 44.9  33.9 0.04
WBC count (109/l), mean  SD 8.3  5.7 8.4  5.2 8.1  5 0.81
Inadequate source control of infection 25 (18.8) 9 (7.9) 16 (84.2) <0.001
Time to biopsy, mean  SD 11.6  7.8 10.5  8.2 12.9  9.2 0.03
Targeted antibacterial therapy 98 (73.6) 90 (78.9) 8 (42.1) <0.001
Time to definitive therapy, mean  SD 10.9  8.9 11.2  9.2 10.2  8.7 0.81
Length of definitive therapy, mean  SD 41.9  26.3 43.2  27 40.1  24.9 0.07
Length of hospitalization, mean  SD 34  17.2 33.6  15.1 34.2  20.5 0.92
Use of FDG-PET/CT 59 (44.3) 57 (50) 2 (10.5) <0.001
30-day mortality 14 (10.5) 12 (10.5) 2 (10.5) 1.0
SD, standard deviation; SUV, standard uptake value; CRP, C-reactive protein; WBC, white blood cell; FDG-PET/CT, 18F-fluorodeoxyglucose positron emission tomography/
computed tomography.
Table 3
Variables independently associated with an undiagnosed etiology of vertebral osteomyelitis (A), clinical cure and failure of therapy (B).
A B
Variables OR 95% CI p-Value Variables OR 95% CI p-Value
Previous antimicrobial therapy 2.3 1.98–3.12 <0.001 Targeted antibacterial therapy 0.34 0.21–0.54 0.01
>5 days delay in performing biopsy 4.2 3.12–7.23 <0.001 Follow-up with FDG-PET/CT 0.45 0.31–0.78 0.02
>2 vertebrae involved 2.87 1.89–4.2 <0.001
Inadequate drainage of infection 4.21 2.87–8.23 <0.001
OR, odds ratio; CI, confidence interval; FDG-PET/CT, 18F-fluorodeoxyglucose positron emission tomography/computed tomography.
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also the high rate of patients on antibiotic therapy at the time of
diagnosis. The latter results in a low rate of positivity for BC and
vertebral biopsy to determine the etiology of infection (Saeed et al.,
2019). As reported in Figure 2, vertebral biopsy without
antimicrobial discontinuation, according to the protocol, was
associated with a high rate of negative results in the present study.
No studies have been performed that have helped guide the
clinician managing patients with significant clinical or radiograph-
ic evidence of VO who also have sterile blood cultures and an initial
non-diagnostic spinal aspiration biopsy result. Obtaining systemic
inflammatory marker levels and diagnosis and follow-up with MRI
may confirm the infection and help monitor the response to
therapy, clarify the presence of abscess in need of drainage, and
identify spinal instability that could benefit from surgical
correction. In previous studies, patients with evidence of
progressive epidural and/or paraspinal soft tissue infection on
follow-up MRI have appeared to be at greater risk of treatment
failure (Kowalski et al., 2007). The frequency and utility of
obtaining follow-up inflammatory laboratory markers (like CRP)
while patients are receiving antimicrobial therapy for VO have not
been established. MRI has some value in assessing the response of
soft tissue infections, but bone and disk abnormalities typically
appear to worsen even in successfully treated patients (Zarrouk
et al., 2007; Carragee, 1997). In the present study, the combination
of FDG-PET/CT plus CRP values at the time of diagnosis and follow-
up seems to be associated with higher accuracy in the monitoring
of the response to therapy. FDG-PET/CT could be used in
association with MRI for the detection of VO, but could alsocontribute to the early determination of the response to therapy.
The study data are in line with those of previous attempts to assess
the treatment response that have relied on quantification of the
SUV value before and after treatment in patients with VO (Nanni
et al., 2012; Kim et al., 2009).
Of interest, the mean SUV was higher for tubercular VO when
compared with pyogenic spondylodiscitis. Delayed diagnosis of a
tubercular etiology may lead to severe consequences, including
permanent spinal damage, and although spinal biopsies often
represent the most accurate diagnostic method, low microbiolog-
ical yields can be associated with tubercular VO. In this setting,
imaging represents a key diagnostic tool to achieve early diagnosis
of the disease and to monitor the response to antibiotic treatment.
As observed previously (Bassetti et al., 2017), the association of
specific FDG-PET/CT features, such as high SUV, with tubercular VO
has been reported but remains to be determined definitively
(Bakheet et al.,1998; Trecarichi et al., 2012). Then, the confirmation
of high SUV values could allow physicians to consider a tubercular
etiology for VO in a more timely manner (Heysell et al., 2013).
In this study population, failure of therapy for VO was observed
in 19 patients (14.3%). The failure rate of patients treated for VO in
most clinical studies has varied between 10% and 30% (Berbari
et al., 2015; Ohtori et al., 2010; Hungenbach et al., 2013; Sehn and
Gilula, 2012; Bhavan et al., 2010; Saeed et al., 2019; Kowalski et al.,
2007; Zarrouk et al., 2007; Carragee, 1997; Nanni et al., 2012; Kim
et al., 2009; Bassetti et al., 2017; Bakheet et al., 1998; Trecarichi
et al., 2012; Heysell et al., 2013; Rissing, 1997). The therapeutic
management of VO patients with treatment failure should be
tailored to the suspected reason for failure. Consultation with a
A. Russo et al. / International Journal of Infectious Diseases 89 (2019) 116–121 121surgeon and infectious disease physician experienced in the
treatment of spinal infections may be warranted in those with
suspected or proven treatment failure. The decision regarding
whether a surgical intervention is warranted needs to be
individualized and should incorporate similar principles as to
whether to perform surgery at the time of VO diagnosis or not
(Valancius et al., 2013).
Some important limitations of this study should be highlighted.
First of all, there was no pre-intervention period, which reduces
the quality of the evidence, since this is a descriptive analysis of
patients managed according to the UDIPROVE protocol. Second,
this was a single-center study with a short follow-up period
(3 months), reducing the generalizability and comparability of the
results. Finally, FDG-PET/CT was not performed for all of the study
population and its routine use could be limited due to the high
costs.
In conclusion, an etiology of infection was obtained in 73.6% of
cases (combination of BC plus vertebral biopsy/drainage), accord-
ing to the UDIPROVE algorithm. Moreover, the combination of the
protocol with the use of FDG-PET/CT for diagnosis and follow-up
was associated with a high rate of clinical cure (85.7%) in this very
difficult-to-treat infection. Finally, antimicrobial therapy at the
time of vertebral biopsy negatively influenced the possibility of
obtaining an etiology of infection.
The rigorous application of antimicrobial washout in combina-
tion with vertebral biopsy and the collection of BC greatly
increased the rate of diagnosis of VO causative pathogens. Finally,
higher SUV values could be associated with a tubercular etiology,
and the combination of SUV plus CRP values could be helpful in
monitoring the response to therapy in all patients.
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